video: Saraubh Mehandru, senior author of the new study, discusses the findings and implications of the research. This material relates to a paper that appeared in the Oct. 3, 2018, issue of Science Translational Medicine , published by AAAS. The paper, by M. Uzzan at Icahn School of Medicine at Mount Sinai in New York, N.Y., and colleagues was titled, "Anti-a4ß7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals."
view more
Credit: Mount Sinai Hospital
在同时罹患炎性肠病(IBD)和HIV的病人中所进行的第一个人体研究发现,给予一种治疗IBD的药物可破坏肠道内感染HIV的T细胞的聚集,后者会形成一个持续的感染库。该化合物叫做维多珠单抗(vedolizumab,VDZ),它或能在某一天对研发治愈HIV的药物提供帮助。尽管现代的抗病毒药物能牵制HIV,但仍然没有治疗药物可将该病毒从体内消灭。一个关键性的路障是该病毒能感染驻留在胃肠(GI)道粘膜组织内的T细胞。减少或清除这一病毒库是HIV研究者的主要目标,但还需做更多的研究来研发安全有效的疗法。Mathieu Uzzan等人在此聚焦于含有a4ß7的T细胞;a4ß7是一种蛋白,它能介导免疫细胞至胃肠道某些部位的迁徙。他们将以a4ß7为标靶的治疗IBD的一线药物VDZ用于6名IBD患者,这组人同时感染了HIV;他们在治疗前后通过血液化验及结肠镜检查对这些人进行了为期30周的监测。VDZ阻止了T细胞在受试者小肠内的簇集,并在研究期间被证明是安全的。作者说,这些结果支持这样的理念,即抗a4ß7疗法或是一个在持续寻求根除HIV的治疗中的重要工具。
###
Journal
Science Translational Medicine
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.